Related Experiment Video
Updated: Jun 2, 2026

A Porcine Heterotopic Heart Transplantation Protocol for Delivery of Therapeutics to a Cardiac Allograft
Published on: February 14, 2022
Surgical therapy of end-stage heart failure in pediatric patients
1Department of Cardiovascular Surgery, Ege University Medical Faculty, Izmir, Turkey.
Insights
Pediatric ventricular assist device (VAD) implantation offers safe circulatory support for children with end-stage heart failure awaiting heart transplantation. This approach improves organ function and is recommended for hemodynamically unstable candidates.
Area of Science:
- Pediatric Cardiology
- Cardiovascular Surgery
- Transplantation Medicine
Background:
- End-stage heart failure in children presents significant challenges.
- Pediatric heart transplantation is a critical treatment option.
- Ventricular assist devices (VADs) can provide mechanical circulatory support.
Purpose of the Study:
- To review the experience with VAD implantation and heart transplantation in pediatric patients.
- To evaluate the safety and efficacy of VADs as a bridge to transplantation.
- To assess the outcomes of heart transplantation in children.
Main Methods:
- Retrospective review of pediatric patients undergoing VAD implantation or heart transplantation.
- Study period from July 2005 to July 2010.
- Inclusion of patients receiving Berlin Heart Excor VAD or heart transplant, with analysis of bridging strategies and follow-up.
Main Results:
- No serious complications during VAD support.
- Heart transplantation mortality rate was 9.1% (1/11).
- VAD implantation improved end-organ function pre-transplant; 4/11 patients experienced controlled rejection episodes.
Conclusions:
- Heart transplantation is highly effective for pediatric end-stage heart failure.
- Pediatric VAD implantation provides safe and satisfactory support for critically ill children.
- VADs should be considered for pediatric heart transplant candidates with poor hemodynamic status.
Objective:
We herein review our experience with ventricular assist device (VAD) implantation and heart transplantation in children with end-stage heart failure.
Methods:
We performed a retrospective nonrandomized review of all patients who underwent insertion of a Berlin Heart Excor VAD or heart transplantation in our clinic. The study spans from July 2005 to July 2010. We transplanted 11 patients of mean age 11.8 ± 4.49 years, 3 of whom with critical hemodynamic situations were bridged to heart transplantation by VAD implantation. Despite the poor right ventricular systolic functions, they did not require right rVAD. In addition, 2 patients who underwent VAD implantation are still awaiting a donor heart. The mean follow-up was 825.27 ± 630.23 days (range, 21-1,888 days).
Results:
There was no serious complication during VAD support. The overall heart transplantation mortality rate was 9.1% (1/11). In all patients, impaired end-organ functions were improved by VAD implantation before the heart transplantation. Cardiac biopsies revealed 4 grade 2R rejection episodes, which were successfully controlled in 3 patients.
Conclusion:
Heart transplantation is highly effective therapy for pediatric patients with end-stage heart failure. Pediatric VAD implantation provided satisfactory safe circulatory support for small children in poor condition on the waiting list. This option should be considered for all pediatric candidates who show a poor hemodynamic status.
Related Concept Videos
Heart Failure VI: Adjunct Therapies
Cardiomyopathy V: Interprofessional Care
Heart Failure V: Medical Management
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Heart Failure IV: Classification and Diagnostic Evaluation
